{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:37:21Z","timestamp":1789519041751,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T00:00:00Z","timestamp":1558396800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T00:00:00Z","timestamp":1558396800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["RD16\/0025\/0019"],"award-info":[{"award-number":["RD16\/0025\/0019"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PT17\/0015\/0042"],"award-info":[{"award-number":["PT17\/0015\/0042"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI16\/01863"],"award-info":[{"award-number":["PI16\/01863"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CIBER-BBN"],"award-info":[{"award-number":["CIBER-BBN"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"PENTA FOUNDATION","award":["EPIICAL Project"],"award-info":[{"award-number":["EPIICAL Project"]}]},{"DOI":"10.13039\/501100000921","name":"European Cooperation in Science and Technology","doi-asserted-by":"publisher","award":["COST CA17140"],"award-info":[{"award-number":["COST CA17140"]}],"id":[{"id":"10.13039\/501100000921","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12951-019-0500-4","type":"journal-article","created":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T14:49:42Z","timestamp":1558450182000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Polyanionic carbosilane dendrimers as a new adjuvant in combination with latency reversal agents for HIV treatment"],"prefix":"10.1186","volume":"17","author":[{"given":"Ignacio","family":"Rela\u00f1o-Rodr\u00edguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Ju\u00e1rez-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Pavicic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0813-4500","authenticated-orcid":false,"given":"Maria \u00c1ngeles","family":"Mu\u00f1oz-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,21]]},"reference":[{"issue":"12","key":"500_CR1","doi-asserted-by":"publisher","first-page":"e27864","DOI":"10.1371\/journal.pone.0027864","volume":"6","author":"C Gutierrez","year":"2011","unstructured":"Gutierrez C, Diaz L, Vallejo A, Hernandez-Novoa B, Abad M, Madrid N, et al. Intensification of antiretroviral therapy with a CCR1 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected. PLoS ONE. 2011;6(12):e27864.","journal-title":"PLoS ONE"},{"issue":"13","key":"500_CR2","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1097\/QAD.0b013e328361d0e1","volume":"27","author":"C Gutierrez","year":"2013","unstructured":"Gutierrez C, Hernandez-Novoa B, Vallejo A, Serrano-Villar S, Abad-Fernandez M, Madrid N, et al. Dynamics of the HIV-1 latent reservoir after discontinuation of the intensification of antiretroviral treatment: results of two clinical trials. AIDS. 2013;27(13):2081\u20138.","journal-title":"AIDS"},{"issue":"7408","key":"500_CR3","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/nature11286","volume":"487","author":"NM Archin","year":"2012","unstructured":"Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature. 2012;487(7408):482\u20135.","journal-title":"Nature"},{"issue":"4","key":"500_CR4","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1084\/jem.20040061","volume":"200","author":"G del Real","year":"2004","unstructured":"del Real G, Jimenez-Baranda S, Mira E, Lacalle RA, Lucas P, Gomez-Mouton C, et al. Statins inhibit HIV-1 infection by down-regulating Rho activity. J Exp Med. 2004;200(4):541\u20137.","journal-title":"J Exp Med"},{"issue":"17","key":"500_CR5","first-page":"4916","volume":"62","author":"R Furumai","year":"2002","unstructured":"Furumai R, Matsuyama A, Kobashi N, Lee KH, Nishiyama M, Nakajima H, et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res. 2002;62(17):4916\u201321.","journal-title":"Cancer Res"},{"issue":"2","key":"500_CR6","doi-asserted-by":"publisher","first-page":"199","DOI":"10.2174\/157016206776055084","volume":"4","author":"J Kulkosky","year":"2006","unstructured":"Kulkosky J, Bray S. HAART-persistent HIV-1 latent reservoirs: their origin, mechanisms of stability and potential strategies for eradication. Curr HIV Res. 2006;4(2):199\u2013208.","journal-title":"Curr HIV Res"},{"issue":"10","key":"500_CR7","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1182\/blood.V98.10.3006","volume":"98","author":"J Kulkosky","year":"2001","unstructured":"Kulkosky J, Culnan DM, Roman J, Dornadula G, Schnell M, Boyd MR, et al. Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood. 2001;98(10):3006\u201315.","journal-title":"Blood"},{"issue":"6","key":"500_CR8","doi-asserted-by":"publisher","first-page":"e11160","DOI":"10.1371\/journal.pone.0011160","volume":"5","author":"R Mehla","year":"2010","unstructured":"Mehla R, Bivalkar-Mehla S, Zhang R, Handy I, Albrecht H, Giri S, et al. Bryostatin modulates latent HIV-1 infection via PKC and AMPK signaling but inhibits acute infection in a receptor independent manner. PLoS ONE. 2010;5(6):e11160.","journal-title":"PLoS ONE"},{"issue":"4","key":"500_CR9","doi-asserted-by":"publisher","first-page":"790","DOI":"10.4161\/hv.23202","volume":"9","author":"TA Rasmussen","year":"2013","unstructured":"Rasmussen TA, Tolstrup M, Winckelmann A, Ostergaard L, Sogaard OS. Eliminating the latent HIV reservoir by reactivation strategies: advancing to clinical trials. Hum Vaccines Immunother. 2013;9(4):790\u20139.","journal-title":"Hum Vaccines Immunother"},{"issue":"1","key":"500_CR10","first-page":"38","volume":"7","author":"JA Zonder","year":"2001","unstructured":"Zonder JA, Shields AF, Zalupski M, Chaplen R, Heilbrun LK, Arlauskas P, et al. A phase II trial of bryostatin 1 in the treatment of metastatic colorectal cancer. Clin Cancer Res. 2001;7(1):38\u201342.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"500_CR11","doi-asserted-by":"publisher","first-page":"e1004071","DOI":"10.1371\/journal.ppat.1004071","volume":"10","author":"DG Wei","year":"2014","unstructured":"Wei DG, Chiang V, Fyne E, Balakrishnan M, Barnes T, Graupe M, et al. Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. PLoS Pathog. 2014;10(4):e1004071.","journal-title":"PLoS Pathog"},{"key":"500_CR12","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/1742-4690-10-67","volume":"10","author":"C Van Lint","year":"2013","unstructured":"Van Lint C, Bouchat S, Marcello A. HIV-1 transcription and latency: an update. Retrovirology. 2013;10:67.","journal-title":"Retrovirology"},{"issue":"1","key":"500_CR13","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/jmv.23738","volume":"86","author":"MN Reis","year":"2014","unstructured":"Reis MN, de Alcantara KC, Cardoso LP, Stefani MM. Polymorphisms in the HIV-1 gp41 env gene, natural resistance to enfuvirtide (T-20) and pol resistance among pregnant Brazilian women. J Med Virol. 2014;86(1):8\u201317.","journal-title":"J Med Virol"},{"key":"500_CR14","first-page":"1281","volume":"11","author":"E Vacas-Cordoba","year":"2016","unstructured":"Vacas-Cordoba E, Maly M, De la Mata FJ, Gomez R, Pion M, Munoz-Fernandez MA. Antiviral mechanism of polyanionic carbosilane dendrimers against HIV-1. Int J Nanomed. 2016;11:1281\u201394.","journal-title":"Int J Nanomed"},{"issue":"41","key":"500_CR15","doi-asserted-by":"publisher","first-page":"12733","DOI":"10.1039\/c2dt31099f","volume":"41","author":"B Rasines","year":"2012","unstructured":"Rasines B, Sanchez-Nieves J, Maiolo M, Maly M, Chonco L, Jimenez JL, et al. Synthesis, structure and molecular modelling of anionic carbosilane dendrimers. Dalton Trans. 2012;41(41):12733\u201348.","journal-title":"Dalton Trans"},{"key":"500_CR16","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1002\/polb.23529","volume":"52","author":"E Arn\u00e1iz","year":"2014","unstructured":"Arn\u00e1iz E, Vacas-Cordoba E, Galan M, Pion M, Gomez R, Mu\u00f1oz-Fernandez M, et al. Synthesis of anionic carbosilane dendrimers via \u201cclick chemistry\u201d and their antiviral properties against HIV. J Polymer Sci. 2014;52:1055\u2013215.","journal-title":"J Polymer Sci"},{"issue":"17","key":"500_CR17","doi-asserted-by":"publisher","first-page":"8776","DOI":"10.1128\/JVI.76.17.8776-8786.2002","volume":"76","author":"O Kutsch","year":"2002","unstructured":"Kutsch O, Benveniste EN, Shaw GM, Levy DN. Direct and quantitative single-cell analysis of human immunodeficiency virus type 1 reactivation from latency. J Virol. 2002;76(17):8776\u201386.","journal-title":"J Virol"},{"issue":"3","key":"500_CR18","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1093\/jac\/dks432","volume":"68","author":"H Arberas","year":"2013","unstructured":"Arberas H, Guardo AC, Bargallo ME, Maleno MJ, Calvo M, Blanco JL, et al. In vitro effects of the CCR17 inhibitor maraviroc on human T cell function. J Antimicrob Chemother. 2013;68(3):577\u201386.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"500_CR19","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1128\/AAC.00733-08","volume":"53","author":"L Bousquet","year":"2009","unstructured":"Bousquet L, Pruvost A, Guyot AC, Farinotti R, Mabondzo A. Combination of tenofovir and emtricitabine plus efavirenz: in vitro modulation of ABC transporter and intracellular drug accumulation. Antimicrob Agents Chemother. 2009;53(3):896\u2013902.","journal-title":"Antimicrob Agents Chemother"},{"issue":"27","key":"500_CR20","doi-asserted-by":"publisher","first-page":"9732","DOI":"10.1039\/C7NR03034G","volume":"9","author":"R Cena-Diez","year":"2017","unstructured":"Cena-Diez R, Garcia-Broncano P, Javier de la Mata F, Gomez R, Resino S, Munoz-Fernandez M. G2-S16 dendrimer as a candidate for a microbicide to prevent HIV-1 infection in women. Nanoscale. 2017;9(27):9732\u201342.","journal-title":"Nanoscale"},{"key":"500_CR21","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ejphar.2017.05.060","volume":"811","author":"P Garcia-Broncano","year":"2017","unstructured":"Garcia-Broncano P, Cena-Diez R, de la Mata FJ, Gomez R, Resino S, Munoz-Fernandez MA. Efficacy of carbosilane dendrimers with an antiretroviral combination against HIV-1 in the presence of semen-derived enhancer of viral infection. Eur J Pharmacol. 2017;811:155\u201363.","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"500_CR22","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.nano.2015.04.013","volume":"11","author":"D Sepulveda-Crespo","year":"2015","unstructured":"Sepulveda-Crespo D, Serramia MJ, Tager AM, Vrbanac V, Gomez R, De La Mata FJ, et al. Prevention vaginally of HIV-1 transmission in humanized BLT mice and mode of antiviral action of polyanionic carbosilane dendrimer G2-S16. Nanomedicine. 2015;11(6):1299\u2013308.","journal-title":"Nanomedicine"},{"key":"500_CR23","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.antiviral.2015.09.014","volume":"123","author":"M Martinez-Bonet","year":"2015","unstructured":"Martinez-Bonet M, Clemente MI, Alvarez S, Diaz L, Garcia-Alonso D, Munoz E, et al. Antiretroviral drugs do not interfere with bryostatin-mediated HIV-1 latency reversal. Antiviral Res. 2015;123:163\u201371.","journal-title":"Antiviral Res"},{"key":"500_CR24","doi-asserted-by":"publisher","first-page":"16445","DOI":"10.1038\/srep16445","volume":"5","author":"M Martinez-Bonet","year":"2015","unstructured":"Martinez-Bonet M, Clemente MI, Serramia MJ, Munoz E, Moreno S, Munoz-Fernandez MA. Synergistic activation of latent HIV-1 expression by novel histone deacetylase inhibitors and bryostatin-1. Sci Rep. 2015;5:16445.","journal-title":"Sci Rep"},{"issue":"6","key":"500_CR25","doi-asserted-by":"publisher","first-page":"899","DOI":"10.2217\/nnm.14.79","volume":"10","author":"D Sepulveda-Crespo","year":"2015","unstructured":"Sepulveda-Crespo D, Sanchez-Rodriguez J, Serramia MJ, Gomez R, De La Mata FJ, Jimenez JL, et al. Triple combination of carbosilane dendrimers, tenofovir and maraviroc as potential microbicide to prevent HIV-1 sexual transmission. Nanomedicine. 2015;10(6):899\u2013914.","journal-title":"Nanomedicine"},{"issue":"3","key":"500_CR26","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.nano.2013.10.002","volume":"10","author":"D Sepulveda-Crespo","year":"2014","unstructured":"Sepulveda-Crespo D, Lorente R, Leal M, Gomez R, De la Mata FJ, Jimenez JL, et al. Synergistic activity profile of carbosilane dendrimer G2-STE16 in combination with other dendrimers and antiretrovirals as topical anti-HIV-1 microbicide. Nanomedicine. 2014;10(3):609\u201318.","journal-title":"Nanomedicine"},{"issue":"13","key":"500_CR27","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1097\/QAD.0b013e328361fa4a","volume":"27","author":"EV Cordoba","year":"2013","unstructured":"Cordoba EV, Arnaiz E, De La Mata FJ, Gomez R, Leal M, Pion M, et al. Synergistic activity of carbosilane dendrimers in combination with maraviroc against HIV in vitro. AIDS. 2013;27(13):2053\u20138.","journal-title":"AIDS"},{"issue":"9","key":"500_CR28","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1128\/CVI.00009-10","volume":"17","author":"OA Gonzalez","year":"2010","unstructured":"Gonzalez OA, Li M, Ebersole JL, Huang CB. HIV-1 reactivation induced by the periodontal pathogens Fusobacterium nucleatum and Porphyromonas gingivalis involves Toll-like receptor 2 [corrected] and 9 activation in monocytes\/macrophages. Clin Vaccine Immunol. 2010;17(9):1417\u201327.","journal-title":"Clin Vaccine Immunol"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-019-0500-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12951-019-0500-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-019-0500-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T23:15:44Z","timestamp":1589930144000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnanobiotechnology.biomedcentral.com\/articles\/10.1186\/s12951-019-0500-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,21]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["500"],"URL":"https:\/\/doi.org\/10.1186\/s12951-019-0500-4","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,21]]},"assertion":[{"value":"13 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"69"}}